specific causes of AKI
Exam-favourite intrinsic causes beyond ATN. AIN: drug-induced in >70% (PPIs, beta-lactams, NSAIDs, ICIs), stop the drug. Rhabdomyolysis: blood on dipstick without RBCs, aggressive crystalloid, don’t replete asymptomatic calcium. Contrast: CAR 2022 risk-stratifies by eGFR; no prophylaxis or RASi hold at eGFR ≥30. Atheroemboli after instrumentation. General approach → acute kidney injury.
- Rhabdomyolysis: hyperkalaemia and compartment syndrome
- ICI nephritis in any patient on immunotherapy with rising Cr → immune checkpoint inhibitor toxicity
- Withholding necessary contrast imaging for fear of CA-AKI at eGFR ≥30 is usually the bigger harm
acute interstitial nephritis
Drug-induced in >70% of cases. Onset typically 7–14 days after exposure but can be weeks to months (especially PPIs).
Common culprits: PPIs (most frequent cause by biopsy series), penicillins, cephalosporins, sulphonamides, fluoroquinolones, NSAIDs, allopurinol, phenytoin. Immune checkpoint inhibitors → AIN weeks to months in (→ immune checkpoint inhibitor toxicity). Other nephrotoxins to name: vancomycin (especially with piperacillin–tazobactam), lithium (chronic interstitial disease, NDI), aminoglycosides, amphotericin, cisplatin, tenofovir, CNIs
Non-drug causes: sarcoidosis, Sjögren syndrome, IgG4-related disease, SLE (tubulointerstitial lupus), infections (Legionella, CMV, EBV, leptospirosis)
Clues: sterile pyuria, WBC casts, non-nephrotic proteinuria, eosinophilia (present in <50%), skin rash and fever (classic triad but uncommon). Urine eosinophils have poor sensitivity and specificity — do not rely on them.
Management: stop the offending drug — most recover within weeks. If no improvement by 5–7 days, consider prednisone 1 mg/kg (max 60 mg) tapered over 4–6 weeks. Biopsy if diagnostic uncertainty or to guide steroid decision. NSAIDs and PPI-induced AIN may have a more indolent course with incomplete recovery.
pigment nephropathy (rhabdomyolysis)
Myoglobin precipitates in tubules → direct toxicity and obstruction, compounded by renal vasoconstriction.
Clues: markedly elevated CK (typically >5000 U/L), dipstick positive for blood with zero RBCs on microscopy (dipstick detects haem in myoglobin), dark urine, hyperkalaemia, hyperphosphataemia, hyperuricaemia, severe hypocalcaemia (early)
Management:
- Aggressive IV crystalloid (target UO 200–300 mL/h) — the single most important intervention
- Do not replete asymptomatic hypocalcaemia — calcium deposits in damaged muscle and may cause rebound hypercalcaemia during recovery
- Monitor for compartment syndrome (the cause may also be the consequence)
- Dialysis if refractory hyperkalaemia or volume overload
contrast-associated AKI — CAR 2022 (Canadian)
| eGFR (mL/min/1.73 m²) | risk with IV contrast | action |
|---|---|---|
| ≥45 | very low–low | no prophylaxis, no follow-up Cr |
| 30–44 | moderate | proceed; consider follow-up Cr; IA contrast + risk factors → prophylaxis |
| <30 (not on dialysis) or AKI | high | individual risk–benefit; IV contrast: no recommendation on volume expansion (no evidence); IA: hydration at clinician’s discretion (0.9% saline preferred, bicarbonate equivalent); Cr at 48–72 h after IA contrast |
- CAR 2022: don’t routinely stop ACEi/ARB or diuretics before or after contrast. KDIGO CKD 2024 differs: in at-risk people (AKI or eGFR <30), consider withholding RAASi ≥48 h before elective contrast CT and nonessential nephrotoxins (NSAIDs, diuretics, aminoglycosides) 24–48 h before and 48 h after
- Metformin: continue if eGFR >30. eGFR ≤30 or AKI → hold at the time of contrast, restart ≥48 h later if Cr stable (<25% rise)
- No hydration if eGFR >30 (IV or IA). Current eGFR within 7 days for inpatients (don’t delay emergent imaging); outpatients without one → screening question about kidney disease
- No NAC, statins or other drugs for prevention. Iso- vs low-osmolar: equivalent; never high-osmolar in at-risk patients (KDIGO 1B). Don’t under-dose CT contrast
- Avoid repeat elective exposures within 48 h if eGFR ≤30, AKI or IA. Life-threatening illness → repeat as needed
- Dialysis patients: no fluid loading, no change to the dialysis schedule, no post-contrast dialysis
- KDIGO 2012 (older): IV volume expansion with NaCl or bicarbonate (1A), oral NAC (2D). CAR 2022 drops NAC and limits hydration to higher-risk patients
- Gadolinium with eGFR <30 → ACR group II/III agents (KDIGO 2024)
- KDIGO AKI 2026 draft (public review, not final): high-risk adults without overload → periprocedural 0.9% saline over hypotonic fluid, bicarbonate or nothing (1B); don’t routinely withhold RASi (2C), aligning with CAR; stop nonessential nephrotoxins 24–48 h before and 48 h after if AKI or eGFR <30; metformin rule as CAR
No routine RASi/diuretic hold; metformin only at eGFR ≤30 or AKI; prophylaxis mainly when eGFR <30. Withholding necessary contrast imaging is usually the bigger harm.
cholesterol atheroemboli
Days to weeks after arterial instrumentation or anticoagulation: subacute, often irreversible decline; livedo, blue toes, eosinophilia, low complement. Supportive; statin.
Prepared 2026-10-27. Not yet verified — check every number against the sources.